Diabetes Drug Candidate AdipoRon Emerges as Unexpected Driver of Leukemia Blood Vessel Growth

A short correspondence published in Molecular Biology Reports has thrust an unlikely molecule into the spotlight of leukemia research: AdipoRon, a synthetic agonist of adiponectin receptors, appears to promote angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through the receptor AdipoR1. The correspondence, authored by Johnny Padulo of the Department of Biomedical Sciences for Health at the University of Milan and published on 7 October 2026, responds to an original research article by Mallardo, Russo, Daniele, Chambery and Nigro that appeared in the same journal on 11 November 2025. Together, the two papers sketch a picture that is at once biologically fascinating and methodologically cautionary, and both deserve careful attention from anyone following the intersection of metabolic signaling and blood cancer.

To understand why this finding matters, it helps to start with adiponectin itself. Adiponectin is a hormone secreted almost exclusively by adipocytes, the fat cells of adipose tissue, and it circulates in remarkably high concentrations in the bloodstream. For years it has been celebrated as a protective adipokine: levels tend to fall in obesity, insulin resistance and type 2 diabetes, and restoring its signaling has been a long-standing therapeutic ambition. Adiponectin exerts its effects by binding to two G-protein-coupled-like receptors, AdipoR1 and AdipoR2, which in turn engage intracellular cascades including AMP-activated protein kinase, or AMPK, a central metabolic master switch. AdipoRon, developed as an orally available small-molecule agonist of these receptors, was designed to mimic adiponectin’s beneficial metabolic actions in patients whose adiponectin signaling is impaired.

Yet adiponectin biology has never been a simple story of good versus bad. The correspondence sits within a literature that documents strikingly context-dependent, even contradictory, effects of the hormone. Shibata, Ouchi, Kihara and colleagues showed in the Journal of Biological Chemistry in 2004 that adiponectin actually stimulates angiogenesis in response to tissue ischemia through AMPK signaling, a beneficial effect when the goal is revascularizing starving tissue. Man, Ng, Xu and colleagues reported in Clinical Cancer Research in 2010 that adiponectin suppresses liver tumor growth and metastasis in nude mice by inhibiting tumor angiogenesis and downregulating Rho kinase, interferon-inducible protein 10 and matrix metalloproteinase 9 signaling, an anti-angiogenic effect in that setting. Cai, Xu, Piao and colleagues demonstrated in Molecular Carcinogenesis in 2016 that adiponectin can induce CXCL1 secretion from cancer cells and promote tumor angiogenesis by driving stromal fibroblast senescence. Roy and Palaniyandi, reviewing the field in Cell Bioscience in 2021, emphasized that adiponectin’s downstream signaling pathways are profoundly tissue-specific. In other words, the same receptor-ligand system can build vessels in one context and strangle them in another.

Against that backdrop, the original article by Mallardo and colleagues made a provocative claim: in B-cell leukemia, activation of adiponectin signaling with AdipoRon does not restrain the disease but instead promotes angiogenesis, and it does so by shifting the balance of pro-angiogenic factors through AdipoR1 specifically. B-cell leukemias, including chronic lymphocytic leukemia and related lymphoproliferative disorders, depend on their microenvironment for survival signals, and the formation of new blood vessels within leukemic niches supplies not only oxygen and nutrients but also paracrine support that can protect malignant cells from chemotherapy. If a diabetes-oriented drug candidate were to enhance that vascular supply, the implications for patient safety would be immediate and serious, particularly because AdipoRon has been proposed in some quarters as a candidate for repurposing in metabolic disease and, paradoxically, in cancer contexts where adiponectin signaling was assumed to be protective.

The mechanistic detail highlighted in the correspondence, that the pro-angiogenic effect is mediated through AdipoR1 rather than AdipoR2, is significant for drug development. The two receptors are not interchangeable. AdipoR1 is generally described as the more abundant isoform in skeletal muscle and is more tightly coupled to AMPK activation, whereas AdipoR2 is more prominent in the liver and is associated with peroxisome proliferator-activated receptor alpha signaling. A compound whose vascular effects run through AdipoR1 therefore engages the very arm of the pathway most associated with metabolic benefit, which complicates any simple strategy of dialing adiponectin signaling up or down. It also suggests that receptor-selective ligands, rather than broad agonists, may be needed if adiponectin-based therapeutics are to be deployed safely in patients who may harbor occult hematologic malignancies.

What makes the Padulo correspondence particularly noteworthy, however, is not only its endorsement of the biological finding but the methodological lens through which it examines the work. The correspondence’s reference list is telling: alongside the original article and the adiponectin literature, it cites Begley and Ellis’s landmark 2012 Nature commentary urging higher standards for preclinical cancer research, Nuzzo’s 2014 Nature news feature on statistical errors in science, and Padulo’s own 2014 Proceedings of the National Academy of Sciences letter on distinguishing signal from noise in statistical analysis. This trio of citations signals a correspondence concerned with reproducibility, statistical power and the interpretation of noisy biological data, issues that have dogged preclinical oncology for over a decade. Begley and Ellis famously reported that industry scientists could replicate only a small fraction of published preclinical cancer findings, and their call for rigor, blinding, replication and transparent statistics has since become a benchmark against which new mechanistic claims are measured.

Reading the correspondence in that light, its contribution is twofold. First, it draws attention to a genuinely surprising result that challenges the prevailing assumption that adiponectin signaling is uniformly tumor-suppressive in hematologic malignancy. Second, it implicitly frames the original finding as a test case for how the field should handle results that cut against expectation: with rigorous statistics, careful receptor-level mechanistic dissection and an awareness of the tissue-specific contingencies documented across the adiponectin literature. The correspondence states that no datasets were generated or analysed during its preparation, confirming its role as a commentary and critique rather than a new experimental study, and its author declares no competing interests. The original article, published a year earlier, remains the primary source of the experimental evidence linking AdipoRon, AdipoR1 and pro-angiogenic factor modulation in B-cell leukemia cells.

For clinicians and translational researchers, the stakes are concrete. AdipoRon has been widely discussed as a potential therapy for metabolic syndrome, and adiponectin agonism has been explored for cardiovascular protection, where promoting angiogenesis in ischemic tissue would be a feature rather than a bug. But a substantial fraction of patients with metabolic disease are older adults, the same demographic in which B-cell leukemias and indolent lymphomas are most common, often undiagnosed and slowly progressive. A drug that stimulates vessel formation within a leukemic niche could, in principle, accelerate disease progression in precisely the population most likely to receive it. The correspondence therefore functions as a safety flag: before adiponectin receptor agonists move further toward the clinic, their effects on hematologic malignancy microenvironments need to be characterized as thoroughly as their metabolic benefits.

For basic scientists, the finding adds a compelling data point to the growing map of adiponectin’s dual personality. The hormone that protects the heart and liver in one setting can feed a tumor’s blood supply in another, and the deciding variable appears to be tissue context, receptor isoform and the specific pro-angiogenic factors a given malignancy deploys. Disentangling which downstream mediators, AMPK and beyond, are recruited in B-cell leukemia cells, and which pro-angiogenic factors rise when AdipoR1 is engaged, will be the obvious next step for experimental follow-up. The correspondence’s emphasis on statistical rigor suggests that such follow-up should be designed with adequate power, independent replication and pre-specified endpoints from the outset.

The exchange also illustrates the healthy function of correspondence sections in scientific journals. A single letter, published on 7 October 2026 in volume 53 of Molecular Biology Reports as article number 1674, can reframe a year-old experimental finding, connect it to a decade-long conversation about reproducibility in cancer research, and redirect the attention of both drug developers and hematologists toward an underappreciated risk. Whether AdipoRon ultimately proves to be a metabolic wonder drug, a vascular hazard for leukemia patients or both, the dialogue between the original authors and their correspondent has already clarified the questions that must be answered next: which receptor, which factors, which context, and how confident can we be that the signal is real.

Subject of Research: Adiponectin receptor signaling and angiogenesis in B-cell leukemia

Article Title: Correspondence to: AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1

Article References: Padulo, J. (2026). Correspondence to: AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1. Molecular Biology Reports, 53(1), Article 1674. https://doi.org/10.1007/s11033-026-12845-0

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12845-0

Keywords: AdipoRon, adiponectin, AdipoR1, angiogenesis, B-cell leukemia, AMPK, pro-angiogenic factors, tumor microenvironment, Molecular Biology Reports, preclinical research, reproducibility, drug repurposing